Mirum Pharmaceuticals share price logo

Mirum Pharmaceuticals

NASDAQ: MIRM

Mid Cap

$98.22

-2.39

(-2.38%)

as on

Mirum Pharmaceuticals Stock Performance

as on September 12, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $97.80
    $103.28
    downward going graph

    0.43%

    Downside

    5.15%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $63.23
    $130.00
    downward going graph

    35.62%

    Downside

    32.36%

    Upside

    downward going graph

Mirum Pharmaceuticals share price movements today

Previous Close
$100.61
Open
$103.12
Volume
442.7K
Market Cap
$6.1B
Day's Low - High
$97.80 - $103.28
52 Week Low - High
$63.23 - $130.00

Mirum Pharmaceuticals Historical Returns

1 Month Return
-0.41 %
3 Month Return
+ 4.57 %
1 Year Return
+ 31.27 %
3 Year Return
+ 230.64 %
5 Year Return
+ 441.6 %

Mirum Pharmaceuticals Stock Fundamentals & Key Indicators

Check Mirum Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.1B

EPS (TTM)

-15.14

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-70.3M

Revenue (TTM)

618.1M

Profit Margin

-139.18%

Return On Equity TTM

-702.97%

Mirum Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Mirum Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$6.1B441.6%NA-139.18%NA
BUY$44.6B614.61%NA0.00%NA
BUY$138.4B181.2%30.5486.04%NA
BUY$56.0B-69.82%-16.99-12.57%NA
BUY$85.2B24.16%19.2884.86%45.660000000000004%

Stock Returns calculator for Mirum Pharmaceuticals Stock including INR - Dollar returns

The Mirum Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Mirum Pharmaceuticals investment value today

Current value as on today

₹1,42,217

Returns

₹42,217

(+42.22%)

Returns from Mirum Pharmaceuticals Stock

₹31,161 (+31.16%)

Dollar Impact

₹11,056 (+11.06%)

Analyst Recommendation on Mirum Pharmaceuticals Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Mirum Pharmaceuticals. Average target price of $138.21

Mirum Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Mirum Pharmaceuticals.

What analysts predicted

28.93%UPSIDE

Target Price

$138.21

Current Price

$98.22

Analyzed by

10 Analysts

Target

$138.21

Mirum Pharmaceuticals target price $138.21, a slight upside of 28.93% compared to current price of $98.22. According to 10 analysts rating.

Indian Investors' Interest in Mirum Pharmaceuticals Stock

Search interest for Mirum Pharmaceuticals Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-42% versus previous 30 day period

Mirum Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
69
77
90
99
111
127
133
148
159
176
Gross Profit
51
57
69
76
88
104
107
120
131
145
Operating Income
-26
-24
-12
-24
-15
-4
2
-4
-63
-42
EBITDA
-15
-14
-4
-14
-4
4
9
4
-779
-11
Interest Expense
3
3
3
3
3
3
3
3
3
2
Depreciation
5
5
6
6
6
6
6
6
6
6
Income Before Tax
-24
-24
-13
-24
-13
-5
2
-4
-789
-65
Income Tax Expense
0
0
0
0
1
0
0
0
0
1
Net Income
-25
-24
-14
-23
-14
-5
2
-5
-790
-67
Net Profit Margin
-36.52%
-31.64%
-15.75%
-23.93%
-13.15%
-4.59%
2.18%
-3.85%
-494.21%
-38.14%

Mirum Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
11
19
77
186
336
521
Gross Profit
-
0
0
17
64
139
255
420
Operating Income
-2
-54
-104
-173
-131
-109
-87
-22
EBITDA
-17
-54
-102
-65
-122
-136
-48
17
Interest Expense
-
2
0
17
15
15
14
14
Depreciation
-
0
0
0
3
6
23
24
Income Before Tax
-17
-52
-103
-83
-142
-162
-86
-21
Income Tax Expense
-4
0
0
0
-6
0
1
1
Net Income
-17
-52
-103
-83
-135
-163
-87
-23
Net Profit Margin
0.00%
0.00%
-938.82%
-438.85%
-176.05%
-87.68%
-26.10%
-4.48%

Mirum Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-24
-14
-23
-14
-5
2
-5
-790
-857
Operating Cash Flow
-3
3
-5
-1
12
39
6
-228
-273
Investing Cash Flow
-72
-18
0
-16
-6
-2
1
-11
-171
Financing Cash Flow
7
3
5
6
8
16
8
270
481
Change in Cash
-69
-10
0
-10
16
53
15
28
34

Mirum Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-52
-103
-83
-135
-163
-87
-23
Operating Cash Flow
-39
-89
-132
-120
-70
10
55
Investing Cash Flow
-127
37
48
7
-107
-90
-23
Financing Cash Flow
127
181
73
109
336
17
40
Change in Cash
-39
130
-10
-3
158
-63
75

Mutual Funds that own Mirum Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Mirum Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
5.211939%
3384227
JANUS INVESTMENT FUND
3.645072%
2366826
LAZARD FUNDS INC
2.388651%
1551004
MUTUAL FUND SERIES TRUST
2.225368%
1444981
SMALLCAP World Fund Inc
1.115648%
724415

Global Institutional Holdings in Mirum Pharmaceuticals

Funds
Holdings
Vanguard
7.02%
iShares
3.63%
SPDR
2.03%
Michael Rockefeller
0.87%
Felix Baker
0.69%

Mirum Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 08 September

    Tue, 06:05 PM

    -

    Mirum Pharmaceuticals appoints Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026.

Insights on Mirum Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 10 quarters, 69.22M → 176.24M (in $), with an average increase of 9.8% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, MIRM stock has moved up by 227.8%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MIRM has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -790.15M → -67.22M (in $), with an average increase of 1075.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 512.4% return, outperforming this stock by 480.2%

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
OrganisationMirum Pharmaceuticals
Headquarters989 East Hillsdale Boulevard, Foster City, CA, United States, 94404
IndustryBiotechnology
CEOMr. Christopher Peetz
E-voting on sharesClick here to vote

Key Management of Mirum Pharmaceuticals

Name

Title

Mr. Peter Radovich M.B.A., Ph.D.

COO & President

Mr. Eric H. Bjerkholt M.B.A., M.S.

Chief Financial Officer

Ms. Erin Campany

Chief People Officer

Ms. Lara Longpre MBA, MSC

Chief Development Officer

Mr. Christopher Peetz

CEO & Director

Dr. Joanne M. J. Quan M.D.

Chief Medical Officer

Dr. Jean-Luc Girardet Ph.D.

Chief Technical Officer

Mr. Andrew McKibben

Senior Vice President, Strategic Finance & Investor Relations

Mr. Douglas T. Sheehy J.D.

Chief Legal Officer & Secretary

Meredith Kiernan

Senior Director of Global Corporate Communications

FAQs

What is Mirum Pharmaceuticals share price today?

Mirum Pharmaceuticals share price today is $98.22 as on at the close of the market. Mirum Pharmaceuticals share today touched a day high of $103.28 and a low of $97.80.

What is the 52 week high and 52 week low for Mirum Pharmaceuticals share?

Mirum Pharmaceuticals share touched a 52 week high of $130.00 on and a 52 week low of $63.23 on . Mirum Pharmaceuticals stock price today i.e. is closed at $98.22,which is 24.45% down from its 52 week high and 55.33% up from its 52 week low.

What is Mirum Pharmaceuticals's market capitalisation today?

Mirum Pharmaceuticals market capitalisation is $0.01T as on .

How to invest in Mirum Pharmaceuticals Stock (MIRM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Mirum Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mirum Pharmaceuticals Shares that will get you 0.0153 shares as per Mirum Pharmaceuticals share price of $98.22 per share as on September 12, 2026 at 8:46 am IST.

What is the minimum amount required to buy Mirum Pharmaceuticals Stock (MIRM) from India?

Indian investors can start investing in Mirum Pharmaceuticals (MIRM) shares with as little as ₹95.55 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.50 in Mirum Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Mirum Pharmaceuticals share’s latest price of $98.22 as on September 12, 2026 at 8:46 am IST, you will get 0.1018 shares of Mirum Pharmaceuticals. Learn more about fractional shares .

What are the returns that Mirum Pharmaceuticals has given to Indian investors in the last 5 years?

Mirum Pharmaceuticals stock has given 441.6% share price returns and 29.74% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?